1. Home
  2. TECX vs CELC Comparison

TECX vs CELC Comparison

Compare TECX & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • CELC
  • Stock Information
  • Founded
  • TECX 2019
  • CELC 2011
  • Country
  • TECX United States
  • CELC United States
  • Employees
  • TECX N/A
  • CELC N/A
  • Industry
  • TECX
  • CELC Medical Specialities
  • Sector
  • TECX
  • CELC Health Care
  • Exchange
  • TECX Nasdaq
  • CELC Nasdaq
  • Market Cap
  • TECX 334.4M
  • CELC 440.0M
  • IPO Year
  • TECX 2018
  • CELC 2017
  • Fundamental
  • Price
  • TECX $19.91
  • CELC $13.35
  • Analyst Decision
  • TECX Buy
  • CELC Strong Buy
  • Analyst Count
  • TECX 6
  • CELC 5
  • Target Price
  • TECX $78.67
  • CELC $30.80
  • AVG Volume (30 Days)
  • TECX 244.3K
  • CELC 168.6K
  • Earning Date
  • TECX 08-13-2025
  • CELC 08-13-2025
  • Dividend Yield
  • TECX N/A
  • CELC N/A
  • EPS Growth
  • TECX N/A
  • CELC N/A
  • EPS
  • TECX N/A
  • CELC N/A
  • Revenue
  • TECX N/A
  • CELC N/A
  • Revenue This Year
  • TECX N/A
  • CELC N/A
  • Revenue Next Year
  • TECX N/A
  • CELC N/A
  • P/E Ratio
  • TECX N/A
  • CELC N/A
  • Revenue Growth
  • TECX N/A
  • CELC N/A
  • 52 Week Low
  • TECX $13.70
  • CELC $7.58
  • 52 Week High
  • TECX $61.07
  • CELC $19.77
  • Technical
  • Relative Strength Index (RSI)
  • TECX 43.97
  • CELC 66.18
  • Support Level
  • TECX $17.97
  • CELC $11.52
  • Resistance Level
  • TECX $20.75
  • CELC $12.54
  • Average True Range (ATR)
  • TECX 1.40
  • CELC 0.66
  • MACD
  • TECX -0.36
  • CELC 0.03
  • Stochastic Oscillator
  • TECX 26.93
  • CELC 97.42

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Share on Social Networks: